Bill & Melinda Gates Medical Research Institute
Gates Medical Research Institute
Member since 2021
Jared Silverman Ph.D. , Head of Translational Discovery
- Upendra Argikar
- Emilio Emini
- Khisi Mduli
- Monicah Otieno
- Betsy Russell
- Kelsey Briggs
The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.
The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase 1 through phase 3) and global regulatory interactions.
Role & Expertise
The institute focuses on programs aimed at reducing the burden of TB, malaria, diarrheal diseases, and maternal, newborn, and child illnesses.
As an affiliate of the Bill & Melinda Gates Foundation, the institute’s programs are focused on disease and health areas of primary focus at the foundation. The interventions under study and development are derived from sources both within and external to the foundation.
Scientific discovery followed by product development and delivery is one formula for saving lives. It has turned HIV from a death sentence into a disease people can live with. It turned smallpox into a disease no one has to live with.
Right now, scientists know more about human biology than they ever have before. They have the computing power to simulate complex biological processes, and to do it incredibly quickly. The universe of the possible keeps expanding.
However, the necessary funding, tools and commitment have only rarely been brought together to serve the needs of the world’s poorest people. It’s time to use the latest innovations to improve all lives. We will combine advances in biomarker profiling of the immune system and infectious organisms and bioassays, quantitative sciences and statistical computing, and expertise in chemistry and manufacturing to move potential solutions from the laboratory into human trials.
We are part of a large community with shared goals, and we know we will reach those goals faster together. We rely on academic researchers, biotechnology and pharmaceutical companies, and global health organizations as partners in our work. We will share what we learn with our partners to accelerate the cycle of innovation.